Tonix Pharma surges on plans to advance mpox vaccine development

Tonix Pharmaceuticals Holding

16/08/2024 12:30

** Shares of Tonix Pharmaceuticals  TNXP.O  rise ~44% to 65
cents premarket
    ** Co says it will advance development of its mpox vaccine
candidate
    ** "We are motivated to advance development for our mpox
vaccine with urgency given the global public health emergency,"
said CEO Seth Lederman
    ** The WHO has declared an outbreak of mpox, a viral
infection that spreads through close contact, represents a
global health emergency for the second time in two years 
    ** Two strains of mpox are now spreading in Congo - the
endemic form of the virus, Clade I, and a new offshoot called
clade Ib 
    ** Tonix's candidate, TNX-801, had earlier prevented
clinical disease and lesions in non-human primates infected with
intratracheal Clade I mpox virus -TNXP    
    ** Up to last close, stock down 96.5% YTD 

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))